JAMA Article Links Increased Long-Term Mortality To Trasylol Use In CABG Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Study published in Feb. 7 issue reporting negative mortality results adds to recent safety concerns regarding aprotinin use and renal dysfunction.
You may also be interested in...
Joint Panel Favors More Postmarketing Studies For Bayer’s Trasylol
Despite the unanimous recommendation for additional pharmacovigilance for safety, the cardio-renal and drug safety committees vote against taking the product off the market.
Joint Panel Favors More Postmarketing Studies For Bayer’s Trasylol
Despite the unanimous recommendation for additional pharmacovigilance for safety, the cardio-renal and drug safety committees vote against taking the product off the market.
Trasylol Could Face Labeling Changes After Joint Advisory Panel
Long-term observational study showing CV-renal risk for Bayer’s Trasylol should be judged in light of potentially inappropriate comparator drugs, FDA says.